Literature DB >> 7876611

A recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin is efficacious as a subunit vaccine in the gerbil model of amebic liver abscess.

C J Soong1, K C Kain, M Abd-Alla, T F Jackson, J I Ravdin.   

Abstract

The 170-kDa subunit of the galactose-inhibitable adherence lectin of Entamoeba histolytica mediates attachment to colonic mucins and host cells. The DNA fragment encoding the 170-kDa subunit was produced by polymerase chain reaction (PCR) and divided into four sections by restriction endonucleases. The third section (designated LC3, base pairs 2273-3397) encodes a cysteine-rich fusion protein that was recognized by adherence-inhibitory anti-lectin monoclonal antibodies and serum antibodies from 95% of subjects with amebic liver abscess. Immunization of gerbils with purified recombinant LC3-encoded protein (10 micrograms) with Titermax adjuvant elicited a high-titer serum anti-LC3 IgG antibody response and protective immunity against intrahepatic challenge with 0.5 x 10(6) virulent axenic trophozoites (strain HM1:IMSS; 71% vaccine efficacy, P < .01). In summary, a recombinant cysteine-rich portion of the 170-kDa lectin subunit was highly antigenic, immunogenic, and effective as a subunit vaccine in an experimental animal model of amebic liver abscess.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876611     DOI: 10.1093/infdis/171.3.645

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Diagnosis of invasive amebiasis by enzyme-linked immunosorbent assay of saliva to detect amebic lectin antigen and anti-lectin immunoglobulin G antibodies.

Authors:  M D Abd-Alla; T F Jackson; S Reddy; J I Ravdin
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

3.  Protection against invasive amebiasis by a single monoclonal antibody directed against a lipophosphoglycan antigen localized on the surface of Entamoeba histolytica.

Authors:  A Marinets; T Zhang; N Guillén; P Gounon; B Bohle; U Vollmann; O Scheiner; G Wiedermann; S L Stanley; M Duchêne
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

4.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 7.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 8.  The future for vaccine development against Entamoeba histolytica.

Authors:  Jeanie Quach; Joëlle St-Pierre; Kris Chadee
Journal:  Hum Vaccin Immunother       Date:  2014-02-06       Impact factor: 3.452

9.  Evaluation of recombinant fragments of Entamoeba histolytica Gal/GalNAc lectin intermediate subunit for serodiagnosis of amebiasis.

Authors:  Hiroshi Tachibana; Xun-Jia Cheng; Gohta Masuda; Noriyuki Horiki; Tsutomu Takeuchi
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 10.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.